Market Spotlight: Myelofibrosis (MF)


Report
44 Pages
June 2021
Region: Global
Citeline
ID: 4421371

This Market Spotlight report covers the Myelofibrosis (MF) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

The publisher estimates that in 2019, there were 49,500 prevalent cases of myelofibrosis in adults aged 50 years and older worldwide, and forecasts that number to increase to 60,700 prevalent cases by 2028.
Bristol Myers Squibb’s Inrebic and Incyte’s Jakafi are the only marketed drugs for myelofibrosis. These drugs are administered via the oral route.
The majority of industry-sponsored drugs in active clinical development for myelofibrosis are in Phase II, with one drug in the NDA/BLA stage.
Therapies in development for myelofibrosis focus on a wide variety of targets. The majority of the pipeline drugs are administered via the oral route.
High-impact upcoming events for drugs in the myelofibrosis space comprise topline Phase III trial results for pacritinib, Reblozyl, momelotinib, and imetelstat, as well as an estimated PDUFA date for pacritinib.
The overall likelihood of approval of a Phase I hematologic asset is 8.6%, and the average probability a drug advances from Phase III is 59.1%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.6 years in the overall oncology space
The distribution of clinical trials across Phase I–IV indicates that the majority of trials for myelofibrosis have been in the early and mid-phases of development, with 80% of trials in Phase I–II, and only 20% in Phase III–IV.
The US has a substantial lead in the number of myelofibrosis clinical trials globally. Germany leads the major European markets, while Israel has the top spot in Asia.
Novartis has the highest number of completed clinical trials for myelofibrosis, with 15 trials.
Novartis leads industry sponsors with the highest overall number of clinical trials for myelofibrosis, followed by Incyte.

OVERVIEWKEY TAKEAWAYSDISEASE BACKGROUND

TREATMENT

Anemia
Splenomegaly
Curative treatment

EPIDEMIOLOGYMARKETED DRUGSPIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

Bomedemstat for Myelofibrosis (December 5, 2020)
Momelotinib for Myelofibrosis (December 5, 2020)
Pelabresib for Myelofibrosis (December 5, 2020)
Momelotinib for Myelofibrosis (May 6, 2020)
Navitoclax for Myelofibrosis (December 9, 2019)
Reblozyl for Myelofibrosis (November 6, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

BMS Buoyed By EU Approval Of Myelofibrosis Drug
EU Approvals Beckon For Inrebic & Novel Adalimumab Biosimilar
CTI’s Pacritinib Rolls Toward A Return
Winners & Losers: A Deep-Dive Into The EMA’s PRIME Scheme

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

Nippon Shinyaku Licenses Menarini’s Tagraxofusp For Japan
Bristol Acquisition Of Forbius Driven By TGF-beta Assets

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

Sponsors by status
Sponsors by phase

BIBLIOGRAPHYAPPENDIX

LIST OF FIGURES

Figure 1: Trends in prevalent cases of myelofibrosis, 2019–28
Figure 2: Overview of pipeline drugs for myelofibrosis in the US
Figure 3: Pipeline drugs for myelofibrosis, by company
Figure 4: Pipeline drugs for myelofibrosis, by drug type
Figure 5: Pipeline drugs for myelofibrosis, by classification
Figure 6: Momelotinib for Myelofibrosis (May 6, 2020): Phase III - Simplify 2 (vs Best Available Therapy)
Figure 7: Reblozyl for Myelofibrosis (November 6, 2019): Phase II - MF-001
Figure 8: Key upcoming events in myelofibrosis
Figure 9: Probability of success in the hematologic pipeline
Figure 10: Clinical trials in myelofibrosis
Figure 11: Top 10 drugs for clinical trials in myelofibrosis
Figure 12: Top 10 companies for clinical trials in myelofibrosis
Figure 13: Trial locations in myelofibrosis
Figure 14: Myelofibrosis trials status
Figure 15: Myelofibrosis trials sponsors, by phase

LIST OF TABLES

Table 1: Prevalent cases of myelofibrosis, 2019–28
Table 2: Marketed drugs for myelofibrosis
Table 3: Pipeline drugs for myelofibrosis in the US
Table 4: Bomedemstat for Myelofibrosis (December 5, 2020)
Table 5: Momelotinib for Myelofibrosis (December 5, 2020)
Table 6: Pelabresib for Myelofibrosis (December 5, 2020)
Table 7: Momelotinib for Myelofibrosis (May 6, 2020)
Table 8: Navitoclax for Myelofibrosis (December 9, 2019)
Table 9: Reblozyl for Myelofibrosis (November 6, 2019)
Table 10: Historical global sales, by drug ($m), 2016–20
Table 11: Forecasted global sales, by drug ($m), 2021–25

Table of Contents

Related Topics

Related Reports

Myelofibrosis (MF) - Market Insight, Epidemiology and Market Forecast - 2034

Post-Polycythemia Vera Myelofibrosis - Pipeline Insight, 2024

Primary Myelofibrosis Market Report and Forecast 2024-2032

Global Secondary Myelofibrosis Therapeutics Market Report and Forecast 2024-2032

Post-Polycythemia Vera Myelofibrosis Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application